Literature DB >> 3567153

Altered expression of glycosaminoglycans in metastatic 13762NF rat mamma adenocarcinoma cells.

P A Steck, P H Cheong, M Nakajima, W K Yung, R P Moser, G L Nicolson.   

Abstract

A difference in the expression and metabolism of sulfated glycosaminoglycans between rat mammary tumor cells derived from a primary tumor and those from its metastatic lesions has been observed. Cells from the primary tumor possessed about equal quantities of chondroitin sulfate and heparan sulfate on their cell surfaces but released fourfold more chondroitin sulfate than heparan sulfate into their medium. In contrast, cells from distal metastatic lesions expressed approximately 5 times more heparan sulfate than chondroitin sulfate in both medium and cell surface fractions. This was observed to be the result of differential synthesis of the glycosaminoglycans and not of major structural alterations of the individual glycosaminoglycans. The degree of sulfation and size of heparan sulfate were similar for all cells examined. However, chondroitin sulfate, observed to be only chondroitin 4-sulfate, from the metastases-derived cells had a smaller average molecular weight on gel filtration chromatography and showed a decreased quantity of sulfated disaccharides upon degradation with chondroitin ABC lyase compared to the primary tumor derived cells. Major qualitative or quantitative alterations were not observed for hyaluronic acid among the various 13762NF cells. The metabolism of newly synthesized sulfated glycosaminoglycans was also different between cells from primary tumor and metastases. Cells from the primary tumor continued to accumulate glycosaminoglycans in their medium over a 72-h period, while the accumulation of sulfated glycosaminoglycans in the medium of metastases-derived cells showed a plateau after 18-24 h. A pulse-chase kinetics study demonstrated that both heparan sulfate and chondroitin sulfate were degraded by the metastases-derived cells, whereas the primary tumor derived cells degraded only heparan sulfate and degraded it at a slower rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567153     DOI: 10.1021/bi00378a007

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  Sulfated glycoconjugate determinants recognized by monoclonal antibody, SG-1, correlate with the experimental metastatic ability of KHT fibrosarcoma cells.

Authors:  J F Harris; D W Beaton
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

2.  Ultrastructural localization and internalization of proteoglycan epitopes in a human non-Hodgkin (B) lymphoma.

Authors:  J Timár; I Kovalszky; A Bánkfalvi; L Kopper
Journal:  Histochemistry       Date:  1990

3.  Two human melanoma xenografts with different metastatic capacity and glycosaminoglycan pattern.

Authors:  J Timár; I Kovalszky; S Paku; K Lapis; L Kopper
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 function.

Authors:  Katarzyna Koltowska; Kazuhide S Okuda; Marleen Gloger; Maria Rondon-Galeano; Elizabeth Mason; Jiachen Xuan; Stefanie Dudczig; Huijun Chen; Hannah Arnold; Renae Skoczylas; Neil I Bower; Scott Paterson; Anne Karine Lagendijk; Gregory J Baillie; Ignaty Leshchiner; Cas Simons; Kelly A Smith; Wolfram Goessling; Joan K Heath; Richard B Pearson; Elaine Sanij; Stefan Schulte-Merker; Benjamin M Hogan
Journal:  Nat Cell Biol       Date:  2021-11-08       Impact factor: 28.824

5.  Comparative study on Lewis lung tumour lines with 'low' and 'high' metastatic capacity. III. Glycosaminoglycan synthesis, transport and degradation in cell lines.

Authors:  G Pogány; E Moczar; A Jeney; J Timár; F Timár; K Ditrói; K Lapis
Journal:  Clin Exp Metastasis       Date:  1989 Nov-Dec       Impact factor: 5.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.